Get Your Own Businessabc AI Visibility ID
Boost AI visibility, credibility, and discoverability
Immunocore was founded in 2008 as a spinout of MediGene AG, which acquired Avidex in 2006. The core technology was spun out of Oxford University in 1999 by Dr Bent Jakobsen into Avidex Ltd.In July 2015, Immunocore announced the completion of an initial $320 million private financing round, Europe's largest ever financing round by a private life sciences company. Fidelity Management & Research Company, Woodford Investment Management, Malin Corporation, Eli Lilly and Company, and RTW Investments all participated in this fundraise along with other unnamed investors and existing shareholders.In September 2017, the Bill & Melinda Gates Foundation announced a $40 million investment in Immunocore to accelerate the development of Immunocore’s ImmTAV and ImmTAB therapeutics.In March 2020, Immunocore announced the closing of its $130 million Series B private financing round. In January 2021, Immunocore announced the closing of its $75 million Series C round. Immunocore went public in February 2021, with closing announced on February 9, 2021.
